Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic ...

Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.

sBLA accepted for Priority Review Nipocalimab (Johnson & Johnson) Human monoclonal antibody that blocks FcRn and decreases levels of circulating immunoglobulin G antibodies Treatment of generalized ...

After hours: 14 March at 18:55:07 GMT-4 Loading Chart for ARGX ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 278.69 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...

Find Additional Treatment Centers at: ...